Loftsson et al., 2002 - Google Patents
Self‐association and cyclodextrin solubilization of drugsLoftsson et al., 2002
- Document ID
- 11093103787924611297
- Author
- Loftsson T
- Magnúsdóttir A
- Másson M
- Sigurjónsdóttir J
- Publication year
- Publication venue
- Journal of pharmaceutical sciences
External Links
Snippet
Phase‐solubility diagrams are frequently used to calculate stoichiometry of drug/cyclodextrin complexes. Linear diagrams (AL‐type systems) are thought to indicate that the complexes are first order with respect to cyclodextrin and first or higher order with respect to the drug …
- 229920000858 Cyclodextrin 0 title abstract description 144
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
- A61K47/48961—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the conjugate being in the form of a host-guest, i.e. being an inclusion complex, e.g. clathrate, cavitate, fullerene
- A61K47/48969—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the conjugate being in the form of a host-guest, i.e. being an inclusion complex, e.g. clathrate, cavitate, fullerene inclusion being performed with a cyclodextrin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/30—Macromolecular compounds
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar, pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANO-TECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANO-STRUCTURES; MEASUREMENT OR ANALYSIS OF NANO-STRUCTURES; MANUFACTURE OR TREATMENT OF NANO-STRUCTURES
- B82Y5/00—Nano-biotechnology or nano-medicine, e.g. protein engineering or drug delivery
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Loftsson et al. | Self‐association and cyclodextrin solubilization of drugs | |
| Kim et al. | Solubility enhancement and application of cyclodextrins in local drug delivery | |
| Loftsson et al. | The effects of organic salts on the cyclodextrin solubilization of drugs | |
| Loftsson et al. | Self-association of cyclodextrins and cyclodextrin complexes | |
| Másson et al. | Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing | |
| Loftsson et al. | Pharmaceutical applications of cyclodextrins: basic science and product development | |
| Magnusdottir et al. | Self association and cyclodextrin solubilization of NSAIDs | |
| Loftsson et al. | Evaluation of cyclodextrin solubilization of drugs | |
| Cavalli et al. | Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with β-cyclodextrins | |
| Al-Marzouqi et al. | Phase solubility and inclusion complex of itraconazole with β-cyclodextrin using supercritical carbon dioxide | |
| Williams III et al. | Characterization of an inclusion complex of cholesterol and hydroxypropyl-β-cyclodextrin | |
| Tønnesen et al. | Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability | |
| Kiss et al. | Evaluation of the cytotoxicity of β-cyclodextrin derivatives: Evidence for the role of cholesterol extraction | |
| Zheng et al. | Physicochemical and structural characterization of quercetin-β-cyclodextrin complexes | |
| Messner et al. | Self-assembled cyclodextrin aggregates and nanoparticles | |
| Loftsson et al. | Carvedilol: solubilization and cyclodextrin complexation: a technical note | |
| Messner et al. | Self-assembly of cyclodextrin complexes: Effect of temperature, agitation and media composition on aggregation | |
| Redenti et al. | Drug/cyclodextrin/hydroxy acid multicomponent systems. Properties and pharmaceutical applications | |
| Cirri et al. | Simultaneous effect of cyclodextrin complexation, pH, and hydrophilic polymers on naproxen solubilization | |
| Messner et al. | Self-assembly of cyclodextrin complexes: aggregation of hydrocortisone/cyclodextrin complexes | |
| Duan et al. | Cyclodextrin solubilization of the antibacterial agents triclosan and triclocarban: formation of aggregates and higher-order complexes | |
| Okimoto et al. | Applicability of (SBE) 7m-β-CD in controlled-porosity osmotic pump tablets (OPTs) | |
| Piel et al. | Development of a non-surfactant parenteral formulation of miconazole by the use of cyclodextrins | |
| Göktürk et al. | A study on solubilization of poorly soluble drugs by cyclodextrins and micelles: complexation and binding characteristics of sulfamethoxazole and trimethoprim | |
| Másson et al. | Stabilisation of ionic drugs through complexation with non-ionic and ionic cyclodextrins |